SPHINGOSINE 1-PHOSPHATE LYASE INSUFFICIENCY SYNDROME (SPLIS) AS A CAUSE OF PRIMARY ADRENAL INSUFFICIENCY AND PRIMARY HYPOGONADISM

R. Kwong1, A. Maharaj1, L. Metherell1, R. Prasad1
1. William Harvey Research Institute, Queen Mary University of London, London, UK.

INTRODUCTION

- Sphingosine 1-phosphate lyase insufficiency syndrome (SPLIS) was initially described in 2017 as a novel condition affecting sphingolipid metabolism.
- Presenting features: nephrotic syndrome and primary adrenal insufficiency (PAI) and to a lesser extent ichthyosis, neurological disease and lymphopenia.
- Additional endocrine presentation with primary hypothyroidism and primary hypogonadism.

AIM

To interrogate the endocrine aspect of the syndrome we reviewed clinical data within our patient cohort with SPLIS and those within the wider literature.

METHOD

- Literature review on published clinical case reports was done on pubmed using search terms “SGPL1 deficiency” and “S1P lyase deficiency”.
- Patient data were retrieved from our previously collected cohort database.

RESULTS

- Total of 45 published cases to date.
- SPLIS is associated with high mortality (n=23/45, 51%; 4 of these in utero).
- Approximately 64% of patients (n=29/45) presented with at least one form of endocrinopathy, PAI being the most common presentation (Figure 1).
- The vast majority of those with PAI also had nephrotic syndrome (86%).
- Amongst 3 kindreds, 3 patients presenting with PAI alone, and 1 patient with PAI and neurological disease, shared the same SGPL1 mutation, c.665 G>A; p.Arg222Gln.
- Nevertheless, 6 other patients with this mutation manifested both PAI and nephrotic syndrome.
- No clear genotype-phenotype correlations observed (Figure 2).

CONCLUSIONS

- SPLIS is unique amongst sphingolipid disorders in presenting with significant endocrinopathy.
- Endocrine dysfunction needs to be considered at diagnosis and surveillance undertaken for evolving disease.
- SPLIS should also be considered in the differential diagnosis of PAI alone.

REFERENCES


ACKNOWLEDGEMENTS

- Barts Charity and MRC for funding this project

CONTACT INFORMATION

Email: r.kwong@qmul.ac.uk

Figure 1: Breakdown of patients’ presenting endocrinopathies
• Sphingosine 1-phosphate lyase insufficiency syndrome...n=8/8); median age = 0.25 yr.

Table 1: Patients’ Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Primary adrenal disease (~60%)</th>
<th>Primary gonadal disease (~18%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of Onset</td>
<td>Range= 0-11 yr</td>
<td>Median= 1.17 yr</td>
</tr>
<tr>
<td>Sex</td>
<td>Male: Female Ratio 2:1</td>
<td>Males Only</td>
</tr>
<tr>
<td>Clinical features/ Imaging findings</td>
<td>Adrenal Califications (n=13/15, 87%)</td>
<td>Enlarged Adrenal (n=2/15, 13%)</td>
</tr>
<tr>
<td></td>
<td>Microphallus (n=7/8)</td>
<td>Cryptorchidism (n=8/8)</td>
</tr>
<tr>
<td>Biochemical features</td>
<td>Glucocorticoid deficiency= 27/27</td>
<td>Mineralocorticoid deficiency= 7/27</td>
</tr>
<tr>
<td></td>
<td>- Raised basal LH and FSH</td>
<td>- exaggerated response to LHRH stimulation</td>
</tr>
<tr>
<td></td>
<td>Mortality</td>
<td>100% (n=8/8); median age = 0.25 yr.</td>
</tr>
</tbody>
</table>

Mortality Approx. 44% (n=12/27) median age = 1.4 yr

CONTACT INFORMATION

Email: r.kwong@qmul.ac.uk

Figure 2

CONTACT INFORMATION

Email: r.kwong@qmul.ac.uk